



100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

ELEMENTAL IMPURITY ASSESSMENT

MATERIAL NAME: POTASSIUM BROMIDE 2022

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying

Page 1 of 5

| TABLE 1: ELEMENTAL IMPURITY ASSESSMENT | Analytical Method: BSI-ATM-0080, Method Validation Report: BSI-RPT-0827 Degradation and Impurity Protocol: BSI-PRL-0154 Degradation and Impurity Report: BSI-RPT-0991 Manufacturing Process: BSI-PRL-0469 Parenteral Specifications (10g/day MDD) | |
|---|---|--|
| Element | Class | ¹Limits 1.0J Target ppm (µg/g) |
| Cadmium (Cd) | 1 | 0.20 |
| Lead (Pb) | 1 | 0.50 |
| Arsenic (As) | 1 | 1.5 |
| Mercury (Hg) | 1 | 0.30 |
| Cobalt (Co) | 2A | 0.50 |
| Vanadium (V) | 2A | 1.0 |
| Nickel (Ni) | 2A | 2.0 |
| Thallium (Tl) | 2B | 0.80 |
| Gold (Au) | 2B | 10 |
| Palladium (Pd) | 2B | 1.0 |
| Iridium (Ir) | 2B | 1.0 |
| Osmium (Os) | 2B | 1.0 |
| Rhodium (Rh) | 2B | 1.0 |
| Ruthenium (Ru) | 2B | 1.0 |
| Selenium (Se) | 2B | 8.0 |
| Silver (Ag) | 2B | 1.0 |
| Platinum (Pt) | 2B | 1.0 |

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying

| TABLE 1: ELEMENTAL IMPURITY ASSESSMENT | Analytical Method: BSI-ATM-0080, Method Validation Report: BSI-RPT-0827 Degradation and Impurity Protocol: BSI-PRL-0154 Degradation and Impurity Report: BSI-RPT-0991 Manufacturing Process: BSI-PRL-0469 Parenteral Specifications (10g/day MDD) | |
|---|---|--|
| Element | Class | ¹Limits 1.0J Target ppm (µg/g) |
| Lithium (Li) | 3 | 25 |
| Antimony (Sb) | 3 | 9.0 |
| Barium (Ba) | 3 | 70 |
| Molybdenum (Mo) | 3 | 150 |
| Copper (Cu) | 3 | 10 |
| Tin (Sn) | 3 | 60 |
| Chromium (Cr) | 3 | 110 |
| Iron (Fe) | 4 | 10 |
| Calcium (Ca) | 4 | 50 |
| Magnesium (Mg) | 4 | 10 |

¹Limits derived from Analytical Method BSI-ATM-0080

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying

| TABLE 2: ELEMENTAL IMPURITY ASSESSMENT | | | | | Analytical Method: BSI-ATM-0080 Method Validation Report: BSI-RPT-0827 Degradation and Impurity Protocol: BSI-PRL-0154 Degradation and Impurity Report: BSI-RPT-0991 Manufacturing Process: BSI-PRL-0469 Parenteral Specifications (10g/day MDD) | | |
|--|-------|-------------------------------------|--|---|---|--|--|
| Element | Class | Limits 1.0J Target ppm (µg/g) | RM Result Lot: RMAT-1221-0044 ppm (µg/g) | ML Result Lot: PMAT-0122-00079 ppm (µg/g) | WC Result Lot: KBRO-0122-00024- PV WC Top ppm (µg/g) | WC Result Lot: KBRO-0122-00024- PV WC Bottom ppm (µg/g) | FG Result Lot: KBRO-0122-00024- PV Drum #1 ppm (µg/g) |
| Cd | 1 | 0.20 | 0.06 | <0.06 | 0.06 | 0.08 | 0.08 |
| Pb | 1 | 0.50 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 |
| As | 1 | 1.5 | <0.45 | 0.67 | <0.45 | <0.45 | <0.45 |
| Hg | 1 | 0.30 | <0.09 | <0.09 | <0.09 | <0.09 | <0.09 |
| Co | 2A | 0.50 | <0.15 | <0.15 | <0.15 | <0.15 | <0.15 |
| V | 2A | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Ni | 2A | 2.0 | <0.60 | <0.60 | <0.60 | <0.60 | <0.60 |
| Tl | 2B | 0.80 | <0.24 | <0.24 | <0.24 | <0.24 | <0.24 |
| Au | 2B | 10 | <3.0 | <3.0 | <3.0 | <3.0 | <3.0 |
| Pd | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Ir | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Os | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Rh | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Ru | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Se | 2B | 8.0 | <2.4 | <2.4 | <2.4 | <2.4 | <2.4 |

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying

| TABLE 2: ELEMENTAL IMPURITY ASSESSMENT | | | | | Analytical Method: BSI-ATM-0080 Method Validation Report: BSI-RPT-0827 Degradation and Impurity Protocol: BSI-PRL-0154 Degradation and Impurity Report: BSI-RPT-0991 Manufacturing Process: BSI-PRL-0469 Parenteral Specifications (10g/day MDD) | | |
|--|-------|-------------------------------------|--|---|---|--|--|
| Element | Class | Limits 1.0J Target ppm (µg/g) | RM Result Lot: RMAT-1221-0044 ppm (µg/g) | ML Result Lot: PMAT-0122-00079 ppm (µg/g) | WC Result Lot: KBRO-0122-00024- PV WC Top ppm (µg/g) | WC Result Lot: KBRO-0122-00024- PV WC Bottom ppm (µg/g) | FG Result Lot: KBRO-0122-00024- PV Drum #1 ppm (µg/g) |
| Ag | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Pt | 2B | 1.0 | <0.30 | <0.30 | <0.30 | <0.30 | <0.30 |
| Li | 3 | 25 | <7.5 | <7.5 | <7.5 | <7.5 | <7.5 |
| Sb | 3 | 9.0 | <2.7 | <2.7 | <2.7 | <2.7 | <2.7 |
| Ba | 3 | 70 | <21 | <21 | <21 | <21 | <21 |
| Mo | 3 | 150 | <45 | <45 | <45 | <45 | <45 |
| Cu | 3 | 10 | <3.0 | <3.0 | <3.0 | <3.0 | <3.0 |
| Sn | 3 | 60 | <18 | <18 | <18 | <18 | <18 |
| Cr | 3 | 110 | <33 | <33 | <33 | <33 | <33 |
| Fe | 4 | 10 | <3.0 | <3.0 | <3.0 | <3.0 | <3.0 |
| Ca | 4 | 50 | <15 | <15 | <15 | <15 | <15 |
| Mg | 4 | 10 | <3.0 | <3.0 | <3.0 | <3.0 | <3.0 |

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying